Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...(rini's orphan drug FIRAZYR(R) reinforces...)

In addition to FIRAZYR, we have acquired seven new products since the start of 2007 which supports delivery of our long term strategy. Shire is in line to deliver another set of excellent results for 2008 and is upgrading its full year guidance for total revenue growth from the mid to high teens to at least 20%."
Q2 2008 Unaudited Results

Q2 2008 Q2 2007

US Non US Non

GAAP Adjustments GAAP(1) GAAP Adjustments GAAP(1)

$M $M $M $M $M $M

Revenues 775.6 - 775.6 574.9 - 574.9

Operating (67.3) 313.8 246.5 (1,775.1) 1,915.8 140.7

(loss)/

income

Net (79.0) 267.1 188.1 (1,811.3) 1,916.6 105.3

(loss)/income

Diluted

(loss)/

earnings

per:

Ordinary (14.6c) 46.2c 31.6c (331.0c) 349.6c 18.6c

share

ADS (43.8c) 138.6c 94.8c (993.0c) 1,048.8c 55.8c

Note: Average exchange rates for Q2 2008 and Q2 2007 were $1.97: GBP1.00

and $1.98: GBP1.00, respectively.

(1) Non GAAP operating income, Non GAAP net income, Non GAAP diluted

earnings per ordinary share and Non GAAP diluted earnings per ADS

exclude intangible asset amortization charges and other items as

described on page 7. For an explanation of why Shire's management

believes that these Non GAAP financial measures are useful to

investors, see page 7. For a reconciliation of these Non GAAP

financial measures to the most directly comparable financial

measures prepared in accordance with US GAAP, see pages 25-28.

2008 Financial Outlook

Apart from the
'/>"/>